

data for these patients until February 2019 or their transition to the adult care unit.

We included 91 patients (68.1% male; mean age at onset, 12.29 years, median age, 13 years; age range, 8 months–17 years) (Fig. 1). The mean duration of follow-up of patients in our unit was 60.45 months (range, 8–165 months). During this time, 66 of the 91 patients (72.53%) relapsed. The strategy used to manage the relapse in 17 patients (25.76%) was a second cycle of EEN, which was effective in 7 of them (41.18%). The mean time elapsed from diagnosis to the second cycle of EEN was 13.76 months (maximum, 110 months). During the follow-up, 65.6% of the patients required escalation of treatment to anti-TNF therapy due to failure of maintenance with thiopurines, with a mean time elapsed from onset to initiation of anti-TNF therapy of 15.29 months (median, 9 months). Of all patients that required biological therapy, 72.9% started with adalimumab (ADA). After a period of combined treatment (anti-TNF and thiopurines), the immunosuppressive treatment was discontinued in 42.2% of patients once they exhibited sustained clinical and endoscopic remission, thus switching to anti-TNF as monotherapy.

Despite the limitations intrinsic in the retrospective design of the study, the results obtained in a large sample of patients ($n=91$ patients) show that although EEN is an effective approach for induction of remission in POCD, a successful-enough approach has yet to be established for subsequent maintenance to prevent the need of biological therapy in the medium term in a significant proportion of patients. Such an approach should involve more strict criteria for the definition of remission and a thorough evaluation of the latter so enable the establishment of more appropriate maintenance therapy.

Funding

This study did not receive any funding.

Conflicts of interest

The authors have no conflicts of interest to declare.

Disopyramide as coadjuvant treatment in obstructive hypertrophic cardiomyopathy[☆]

Disopiramide como tratamiento coadyuvante en miocardiopatía hipertrófica obstructiva

To the editor

The role of left ventricular outflow tract obstruction (LVOTO) in obstructive hypertrophic cardiomyopathy (OHCM) in the paediatric population has yet to be clarified, but it is

[☆] Please cite this article as: Rodríguez-González M, Pérez-Reviriego AA, Castellano-Martínez A, Cascales-Poyatos HM. Disopiramide como tratamiento coadyuvante en miocardiopatía hipertrófica obstructiva. *An Pediatr (Barc)*. 2021;94:253–256.

References

- Navas-López VM, Blasco-Alonso J, Lacasa S, Girón F, Serrano MJ, Vicioso MI, et al. Exclusive enteral nutrition continues to be first line therapy for pediatric Crohn's disease in the era of biologics. *An Pediatr*. 2015;83:47–54.
- Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. *J Gastroenterol*. 2014;49:638–45.
- Swaminath A, Feathers A, Ananthakrishnan A, Falzon L, Li Ferry S. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in pediatric Crohn's disease. *Aliment Pharmacol Ther*. 2017;46:645–56.
- Miele E, Shamir R, Aloï M, Assa A, Braegger C, Bronsky J, et al. Nutrition in paediatric inflammatory bowel disease: a position paper on behalf of the Porto IBD Group of ESPGHAN. *J Pediatr Gastroenterol Nutr*. doi: <https://doi.org/10.1097/MPG.0000000000001896>.
- Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. *J Crohn's Col*. 2014;8:1179–207.

Alicia Isabel Pascual Pérez*, Gemma Pujol Muncunill, Patricia Domínguez Sánchez, Sara Feo Ortega, Javier Martín de Carpi

Unidad para el Cuidado Integral de la Enfermedad Inflamatoria Intestinal Pediátrica (UCIIEI-P), Servicio de Gastroenterología, Hepatología y Nutrición Pediátrica, Hospital Sant Joan de Déu, Barcelona, Spain

* Corresponding author.

E-mail addresses: aliciapascual13@gmail.com, aliciapascual.pediatrics@gmail.com (A.I. Pascual Pérez).

<https://doi.org/10.1016/j.anpede.2020.03.017>

2341-2879/ © 2021 Published by Elsevier España, S.L.U. on behalf of Asociación Española de Pediatría. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



believed to be a risk modifier or minor risk factor for sudden death, and its management and control of the associated symptoms are among the main goals of treatment in these patients.¹ Treatment of LVOTO is recommended in all symptomatic patients and also in asymptomatic patients with a resting peak gradient (PG) greater than 25 mmHg, with the goal of maintaining it below 50 mmHg.¹ Some of the treatment options include surgical septal myectomy and percutaneous alcohol septal ablation, but there is limited experience with these interventions in paediatric patients, and pharmacotherapy is the first step of treatment.² Beta blockers are the first-line therapeutic agents, administered at minimum doses equivalent to 6 mg/kg/day of propranolol.² However, these drugs are frequently contraindicated, cause side effects or are not effective at the maximum tolerated dose, which requires switching treatment or adding second-line drugs. Although calcium channel blockers are the first alternative used in adults, their use in paediatric OHCM is limited, especially in infants aged

Table 1 Characteristics of the paediatric patients with OHCM treated with disopyramide in our hospital in the 2015-2019 period before initiation of disopyramide.

Patient	Sex and age at diagnosis of OHCM	Aetiology	Age and BSA at initiation of disopyramide	Symptoms and NT-proBNP level	ECG/Holter	Echocardiography ^a	Previous medication	Indication of disopyramide	Initial dose of disopyramide
1	Male 7 years	Genetic (index case in family)	10 years 1.17 m ²	Asymptomatic 1245 pg/mL	No history QTc interval, 470 ms	Myocardial thickness 18 mm (z-score, 4.6) Maximum PG 68 mmHg LVEF 73% SMM detected Moderate MI LA enlargement(LA/Ao 1.8)	Bisoprolol 10 mg/24 h	LVOTO refractory to BB, adverse effects of BB (bronchospasm)	10 mg/kg/day
2	Male 8 years	Genetic (index case in family)	11 years 1.36 m ²	CHF (Ross II) 2854 pg/mL	No history of arrhythmia QTc interval, 400 ms	Myocardial thickness 20 mm (z-score, 5.1) Maximum PG 95 mmHg LVEF 73% SMM detected Severe MI LA enlargement(LA/Ao 1.8)	Bisoprolol 10 mg/24 h	LVOTO and symptoms refractory to BB	10 mg/kg/day
3	Female 9 years	Genetic (padre index case in family)	10 years 1.42 m ²	Asymptomatic 1435 pg/mL	No history of arrhythmia QTc interval, 420 ms	Myocardial thickness 21 mm (z-score, 5.3) Maximum PG 73 mmHg LVEF 75% SMM detected Severe MI LA enlargement(LA/Ao 1.8)	Bisoprolol 10 mg/24 h	LVOTO refractory to BB, adverse effects of BB (nightmares)	10 mg/kg/day
4	Female 3 months	Acquired (steroid therapy)	3 months 0.32 m ²	Cardiogenic shock 8524 pg/mL	No history of arrhythmia QTc interval, 385 ms	Myocardial thickness 18 mm (z-score, 7) Maximum PG 88 mmHg LVEF 82% SMM detected Severe MI LA enlargement(LA/Ao 1.8)	Propranolol 15 mg/kg/day	LVOTO and symptoms refractory to BB	10 mg/kg/day

Ao, aorta; BB, beta blockers; BSA, body surface area; CHF, congestive heart failure; LA, left atrium; LA/Ao, left atrial to aortic root ratio; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; MI, mitral valve insufficiency; PG, left ventricular outflow tract peak gradient; SMM, systolic anterior motion of the mitral valve.

^a In every case, myocardial thickness was measured in mm as the width of the interventricular septum in the parasternal long-axis view, and we report the z-score corresponding to this measurement for the BSA at the time of initiation of disopyramide.

Table 2 Outcome of patients treated with disopyramide. The data correspond to the evaluation 48 h after initiation of treatment or at the last follow-up.

Patient (control)	Age and clinical manifestations	Treatment	QTc interval	NT-proBNP	Echocardiography ^a						Adverse events
					Myocardial thickness	Maximum PG	LVEF	SAMM	MI	LA enlargement	
1 (48 h)	7 years Asymptomatic	Bisoprolol (10 mg/24 h) Disopyramide (15 mg/kg/day)	485 ms	127 pg/mL	18 mm (4,6 Z-score)	15 mmHg	65%	No	No	No (LA/Ao 1)	None
1 (last)	14 years Asymptomatic	Bisoprolol (2,5 mg/24 h) Disopyramide (6 mg/kg/day) No myectomy	460 ms	156 pg/mL	22 mm (493 Z-score)	12 mmHg	65%	No	No	No	None Resolution of bronchospasm
2 (48 h)	8 years Asymptomatic	Bisoprolol (10 mg/24 h) Disopyramide (6 mg/kg/day)	427 ms	533 pg/mL	20 mm (509 Z-score)	21 mmHg	62%	No	Mild	No (LA/Ao 1.3)	None
2 (last)	13 years Asymptomatic	Bisoprolol (2,5 mg/24 h) Disopyramide (8 mg/kg/day) No myectomy	415 ms	267 pg/mL	23 mm (553 Z-score)	21 mmHg	62%	No	No	No	None
3 (48 h)	9 years Asymptomatic	Bisoprolol (10 mg/24 h) Disopyramide (15 mg/kg/day)	439 ms	438 pg/mL	19 mm (479 Z-score)	25 mmHg	60%	No	Mild	No (LA/Ao 1.2)	Constipation
3 (last)	11 years Asymptomatic	Bisoprolol (5 mg/24 h) Disopyramide (15 mg/kg/day) No myectomy	450 ms	642 pg/mL	20 mm (503 Z-score)	32 mmHg	58%	No	No	No	Constipation treated with macrogols Resolution of night terrors
4 (48 h)	3 months CHF (Ross II)	Propranolol (15 mg/kg/day) Disopyramide (20 mg/kg/day)	410 ms	4.229 pg/mL	16 mm (645 Z-score)	31 mmHg	63%	Sí	Moderate	Yes (LA/Ao 1.9)	None
4 (last)	6 months asymptomatic	Full discontinuation of medication No myectomy Discharge from paediatric cardiology	405 ms	127 pg/mL	5 mm (103 Z-score)	5 mmHg	68%	No	No	No	None

Ao, aorta; BB, beta blockers; BSA, body surface area; CHF, congestive heart failure; LA, left atrium; LA/Ao, left atrial to aortic root ratio; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; MI, mitral valve insufficiency; OHCM, obstructive hypertrophic cardiomyopathy; PG, left ventricular outflow tract peak gradient; SAMM, systolic anterior motion of the mitral valve.

^a In every case, myocardial thickness was measured in mm as the width of the interventricular septum in the parasternal long-axis view, and we report the z-score corresponding to this measurement for the BSA at the time of the examination.

less than 1 year, in whom serious adverse reactions have been described.² Furthermore, they may even be counter-productive in patients with LVOTO due to their peripheral vasodilating effect.

Disopyramide is a class IA oral antiarrhythmic agent that decreases myocardial excitability and conduction velocity and also possesses anticholinergic, peripheral vasoconstrictive and negative inotropic effects. Its efficacy in controlling LVOTO mainly stems from the 2 latter characteristics, and it has performed better in direct comparisons with other drugs in this particular treatment goal.² There is ample evidence of its efficacy and safety as adjuvant therapy in combination with beta blockers or verapamil in adults. However, the evidence on the use of disopyramide for treatment of paediatric OHCM is scarce. Östman-Smith used disopyramide in 10 patients (mean age, 9 years) out of a cohort of 66 paediatric patients with OHCM for a mean duration of treatment of 8 years, and she found a greater survival and adequate tolerance of the drug in this subset of patients.³ All had severe OHCM, although in some cases disopyramide was not prescribed to manage LVOTO, but as an antiarrhythmic. In addition, all patients were receiving beta blockers at high doses, so the author could not clearly establish a positive impact of survival of disopyramide in itself. O'Connor et al. recently published a case series of 9 patients (mean age, 5.6 years; 4 aged less than 1 year) treated with disopyramide in combination with beta blockers or calcium channel blockers to manage LVOTO, which achieved a median percent reduction of the PG of 58%.⁴ However, treatment was discontinued in 5 patients during the follow-up (median duration, 2.5 years), which was only due to an adverse event (vomiting) in 1 patient. In all other patients, discontinuation was due to the need to perform a septal myectomy (4) or a heart transplant (1), which suggests that the efficacy of disopyramide to control LVOTO is not maintained in the long term. The rest of the articles in the literature are isolated case reports in which disopyramide was used for rescue therapy in patients that did not respond to other drugs.^{5,6}

Our experience with disopyramide for management of paediatric OHCM was similar (Table 1). We present 4 cases of patients that received this drug to manage symptoms of heart failure and LVOTO, systolic anterior motion of the mitral valve with mitral valve insufficiency and left atrial enlargement, detected by echocardiography, that could not be controlled with high-dose beta blockade, with 2 of the patients developing adverse events at the given doses (severe bronchospasm and sleep disturbances). We sought to highlight the quick clinical and echocardiographic improvement observed in our patients within 48 h of initiating treatment, even in an infant with cardiogenic shock secondary to LVOTO, and the absence of serious adverse events at the administered doses (10–20 mg/kg/day), allowing control of the gradient and symptoms in the long term and delaying the need of myectomy and even allowing a reduction in the beta blocker dose until the associated side effects disappeared. The main limitations of the study were its retrospective design, the small and heterogeneous sample and absence of a control group (Table 2).

Based on our own experience and the scarce but favourable evidence currently available, we believe that disopyramide may offer a good alternative for adjuvant treatment in paediatric patients with OHCM and LVOTO refractory to beta blockers or in whom the dose of the latter needs to be reduced due to the development of adverse effects, before stepping up to more aggressive treatment, such as septal myectomy. At present, there is no evidence on the use of disopyramide as monotherapy as an alternative to beta blockers when the latter are contraindicated, but this option could be contemplated, especially in infants aged less than 1 year, even in critical cases, such as the patient in our sample, since in this age group, calcium channel blockers are contraindicated and surgery carries a high risk.

References

1. Norrish G, Cantarutti N, Pissaridou E, Ridout DA, Limongelli G, Elliott PM, et al. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. *Eur J Prev Cardiol*. SAGE PublicationsSage UK: London, England. 2017;24(11):1220–30.
2. Sherrid VM. Drug Therapy for Hypertrophic Cardiomyopathy: Physiology and Practice. *Curr Cardiol Rev*. 2016;12(1):52–65.
3. Östman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. *Fundamental & Clinical Pharmacology*. Blackwell Publishing Ltd. 2010;24(5):637–52.
4. O'Connor MJ, Miller K, Shaddy RE, Lin KY, Hanna BD, Ravishankar C, et al. Disopyramide use in infants and children with hypertrophic cardiomyopathy. *Cardiol Young*. 2018;28(4):530–5.
5. Rodriguez-Gonzalez M, Castellano-Martinez A, Grujic B, Prieto-Heredia MA. Disopyramide as rescue treatment in a critically ill infant with obstructive hypertrophic cardiomyopathy refractory to beta blockers. *J Cardiol Cases*. 2017;15(6):209–13.
6. Teraguchi M, Ikemoto Y, Kobayashi Y. Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy. *Circ J*. 2002;66(7):709–11.

Moisés Rodríguez-González^{a,b,*},
 Álvaro Antonio Pérez-Reviriego^{a,b},
 Ana Castellano-Martínez^{a,b}, Helena María
 Cascales-Poyatos^{a,b}

^a *Sección de Cardiología Pediátrica, Unidad de Gestión Clínica de Pediatría, Hospital Universitario Puerta del Mar, Cádiz, Spain*

^b *Instituto de investigación biomédica e innovación de Cádiz (INiBICA). Unidad de investigación, Hospital Universitario Puerta del Mar, Cádiz, Spain*

* Corresponding author.

E-mail address: doctormoisésrodriguez@gmail.com
 (M. Rodríguez-González).

14 March 2020 22 April 2020

<https://doi.org/10.1016/j.anpede.2020.04.018>
 2341-2879/ © 2021 Published by Elsevier España, S.L.U. on behalf of Asociación Española de Pediatría. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).